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Abstract
Antiretroviral therapy, antibody and CD8+ T cell-mediated responses targeting human
immunodeficiency virus-1 (HIV-1) exert selection pressure on the virus necessitating
escape; however, the ability of CD4+ T cells to exert selective pressure remains unclear.
Using a computational approach on HIV gag/pol/nef sequences and HLA-II allelic data, we
identified 29 HLA-II associated HIV sequence polymorphisms or adaptations (HLA-AP) in
an African cohort of chronically HIV-infected individuals. Epitopes encompassing the pre-
dicted adaptation (AE) or its non-adapted (NAE) version were evaluated for immunogenic-
ity. Using a CD8-depleted IFN-γ ELISpot assay, we determined that the magnitude of CD4+
T cell responses to the predicted epitopes in controllers was higher compared to non-con-
trollers (p<0.0001). However, regardless of the group, the magnitude of responses to AE
was lower as compared to NAE (p<0.0001). CD4+ T cell responses in patients with acute
HIV infection (AHI) demonstrated poor immunogenicity towards AE as compared to NAE
encoded by their transmitted founder virus. Longitudinal data in AHI off antiretroviral therapy
demonstrated sequence changes that were biologically confirmed to represent CD4+
escape mutations. These data demonstrate an innovative application of HLA-associated
polymorphisms to identify biologically relevant CD4+ epitopes and suggests CD4+ T cells
are active participants in driving HIV evolution.
Author Summary
In HIV, CD4+ T cells are best known as the primary targets of infection. Although emerg-
ing data has suggested a more active role in viral pathogenesis, the CD4+ T cell population
remains relatively understudied. Using a novel computational approach, we predicted
29 different epitopes with mutations that potentially represent escape from CD4+ T cell
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responses. The predicted escaped epitopes were found to be less immunogenic than the
wild type forms, suggesting that the identified escapes allow HIV to reduce its visibility to
the immune system. Using longitudinal samples, we were able to show CD4+ T cells driv-
ing viral escape following acute infection. Overall, these findings significantly expand our
knowledge of how CD4+ T cells can exert HIV control and influence HIV evolution, pro-
viding important implications to future vaccine development strategies.
Introduction
The human immunodeficiency virus-1 (HIV-1) has the capacity to escape pressure exerted upon
it by a number of factors including antiretroviral therapy (ART), antibody and CD8+ T cells [1–
4]. Escape implies a level of viral suppression sufficient to provide selection pressure for mutant
genomes to emerge that are no longer sensitive. This has been clearly demonstrated with ART
where combination therapy has been shown effective in controlling HIV [5]. HIV-specific CD8+
T cell and neutralizing antibody responses drive HIV escape and both have been demonstrated
to be important in controlling HIV infection [4,6–8]. Conversely, other innate and adaptive
immune responses have either not been shown to drive HIV escape or have been only demon-
strated to infrequently drive the process calling into question the utility of such responses in over-
all viral control [9]. CD4+ T cell responses have previously been associated with viral sequence
changes, but the scope and relevance of CD4+ T cells on viral control has remained unclear [10–
12]. Recently, viral escape in response to CD4+ T cell responses was definitively demonstrated in
the SIV model, suggesting the potential for CD4+ T cells to mediate HIV control [13].
As CD4+ T cells are the primary targets of HIV infection, their contribution to the adaptive
immune response targeting HIV-1 has been relatively understudied. While the role of these
cells in providing help to B and CD8+ T cells is well documented, a growing body of literature
also implicates HIV-specific CD4+ T cells in exacting immunological control of HIV via direct
antiviral effects [14–16]. This newly attributed function for CD4+ T cells should, if of sufficient
efficacy, select for mutations that allow the virus to evade immune recognition. Using a cohort
of HIV-1 subtype C chronically-infected individuals for whom the HIV sequences (gag, pol
and nef) and HLA-II allelic data were derived, we identified amino acid changes occurring at
the population level that were disproportionately associated with specific HLA-II alleles. These
HLA class II-associated HIV polymorphisms (HLA-AP) were used to predict epitopes encom-
passing them. Based on this adaptation nomenclature, 2 groups of epitopes were generated:
non-adapted epitopes (NAE), epitopes without any evidence of HLA adaptation; and adapted
epitopes (AE), those containing an amino acid associated with adaptation to a specific HLA-II
allele. NAE were demonstrated to be more immunogenic and with enhanced cytotoxic capabil-
ities in eliminating HIV-pulsed targets. Furthermore, we temporally associated HIV-specific
CD4+ T cell responses with the emergence of viral escape following acute HIV infection. Our
findings demonstrate that HLA-AP can predict CD4+ T cell epitopes that escape and that this
viral escape is more common than previously appreciated, suggesting a role for CD4+ T cell
responses in HIV control.
Results
HIV-1 adaptation based on HLA class-II-associated HIV polymorphisms
Although HLA-I associated HIV polymorphisms have been used extensively to identify signa-
tures of CD8+ T cell induced escape [17–20], application of a similar methodology for HLA-II
HLA-II Adaptations and HIV Infection
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associations has not previously yielded any HIV-1 polymorphisms. Using sequences from
HIV-1 gag, pol, and nef, and HLA-II allelic data from the Zambian cohort of 348 chronic HIV
subtype C infected patients, HLA-II specific adaptations at the population level were identified
computationally. The approach yielded 29 unique polymorphisms predicted to represent
escape mutations in the context of a CD4+ T cell epitope (Table 1).
CD4+ T cell epitopes predicted by HLA-II associated HIV polymorphisms
are immunogenic during chronic HIV infection
Using the predicted class II polymorphisms, their respective HLA-II allele, and an in silico predic-
tion algorithm [21], we generated a panel of peptides containing potential CD4+ T cell epitopes.
Epitopes containing a predicted polymorphism represent an adapted epitope or AE, while their
Table 1. List of HLA-II associated HIV-1 polymorphisms.
Protein Positiona HLA-II polymorphism Non-adaptedb Consensusc HLA-IId
Gag 112 K - K DQB1*06:03
Gag 147 L I I DQB1*02
Gag 247 I - I DQB1*06
Gag 339 S P P DRB1*13
Pol 17 H S S DQB1*02:01
Pol 68 T S T DQB1*05
Pol 161 E D E DQB1*04:02
Pol 208 D E E DQB1*05
Pol 215 I V V DRB1*08
Pol 333 V I I DRB1*01:02
Pol 362 K Q Q DQB1*03
Pol 430 K - K DQB1*06:02
Pol 433 Y V V DQB1*02:02
Pol 490 D Q Q DRB1*10:01
Pol 499 D E E DRB1*09:01
Pol 815 F Y F DQB1*03:03
Pol 984 R K R DQB1*06:04
Nef 16 I V V DQB1*02:01
Nef 20 L M M DQB1*03
Nef 24 A E E DRB1*03
Nef 35 R Q R DQB1*06:11
Nef 45 N S S DQB1*02:01
Nef 88 G S S DQB1*04
Nef 104 Q K Q DQB1*05
Nef 135 F Y Y DQB1*06:02
Nef 157 S/T N N DRB1*11:01/DQB1*02:01
Nef 168 L M M DQB1*04:02
Nef 188 G R R DQB1*06:02
Nef 192 R H H DQB1*02:01
aAmino-acid (AA) position based on HXB2 numbering
bThe corresponding non-adapted AA at the polymorphic position; dash indicates lack of non-adapted AA predicted at that position
cThe corresponding consensus HIV-1 clade B AA at the polymorphic position
dPredicted HLA-II allele associated with this AA polymorphism
doi:10.1371/journal.ppat.1005111.t001
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non-adapted (NAE) counterpart contains an amino acid with no evidence of adaptation, fre-
quently the consensus sequence (S3 Table). Immunogenicity has not previously been defined for
the predicted epitopes, and of the 29 unique prediction sites, 12 are entirely novel with no over-
lapping epitopes previously described (www.hiv.lanl.gov, HIVMolecular Immunology Data-
base). For the remaining 17, partially overlapping epitopes, restricted by other HLA-II alleles,
were reported. We tested the immunogenicity of these AE and NAE in a CD8-depleted IFN-γ
ELISpot assay. Depletion of CD8+ cells prior to aliquoting cells was equally efficient when per-
formed on PBMCs from both controller or non-controller donors. Thus, the number of CD4+ T
cells placed in ELISpot wells was similar for all donors tested (S1 Fig). We first tested pools of
peptides containing the identified AE and NAE to screen for responses in 10 HIV seronegative
(SN) donors, 14 chronic HIV-infected (CHI) patients with viral loads>10,000 copies (Non-Con-
trollers, NC), and 14 CHI patients with viral load<2,000 copies (Controllers, C) (Tables 2 and
S1). Although there were differences in the HLA-II alleles represented in the controllers and
non-controllers, this did not reach statistical significance. Initial screening demonstrated HIV-
specific CD4+ T cell responses to these peptide pools in CHI patients. The magnitude of response
by controllers was significantly greater as compared to both seronegative controls and non-con-
trollers (Fig 1A). We observed each predicted CD4+ epitope to be immunogenic in at least one
tested individual. Among controllers, we detected a response to each of the 29 tested epitopes; in
contrast, we were only able to detect responses to 13 (45%) of the epitopes among all non-con-
trollers (Fig 1B). A total of 8 patients (5/14 controllers and 3/14 non-controllers) had a confirmed
mapped response to at least one tested epitope. For 43% of the mapped responses, the donor had
the predicted HLA-II allele, whereas the remaining 57% of the time, the donor had a positive
response despite not having the predicted allele.
To evaluate the accuracy of the predicted epitopes and their associated HLA-II alleles, we
sought to confirm that at least some of the observed positive responses were presented to the
CD4+ T cells by their computationally predicted HLA-II alleles. To do so, we used single HLA-II
allele transfected RM3 cell lines as antigen presenting cells (APC) and in vitro expanded CD4+ T
Table 2. Summary of clinical features and demographic characteristics of the chronic cohort.
Group HIV controller (C) HIV non-controller (NC)
Number of males 10/14 (71%) 13/14 (93%)
Racea
CAU 3/14 (21%) 8/14 (57%)
AA 11/14 (79%) 6/14 (43%)
Risk groupb
MSM 6/14 (43%) 12/14 (86%)
Heterosexual 6/14 (43%) 1/14 (7%)
IVDU 2/14 (14%) 1/14 (7%)
Clinicalc
CD4* 853 465
Plasma VL** 194 25500
aCAU = Caucasian; AA = African-American
bMSM = Men who have sex with men; IVDU = IV drug user
cAbsolute CD4 counts (cells/uL) and plasma VL (HIV-1 RNA copies/mL) are represented as median values;
all patients are ART naïve.
*, p = 0.001 between controller and non-controller CD4 counts
**, p < 0.0001 between controller and non-controller plasma VL
doi:10.1371/journal.ppat.1005111.t002
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cell lines as effectors [22,23]. CD8-depleted PBMCs from two donors previously identified
to have a positive ex vivo response were expanded and then exposed to peptide-pulsed APC
expressing either the HLA-II allele associated with the adapted polymorphism or a mismatched
allele. In these cases (S2 Fig), the predicted HLA-II restriction was shown to match the relevant
allele of the APC, as the highest magnitude IFN-γ ELISpot response was detected when the pep-
tide was presented by an RM3 cell line expressing the polymorphism-associated HLA-II allele.
Adapted epitopes (AE) are poorly immunogenic in chronic infection
We next investigated differences in immunogenicity between adapted and non-adapted epi-
topes. Each identified polymorphism represents a prediction of HLA-II-mediated immune
pressure at a single amino acid. Based on this, we hypothesized reduced immunogenicity for
AE as compared to NAE. We compared the magnitude of positive IFN-γ responses from the
ELISpot assays for NAE/AE pairs from CD8-depleted PBMC taken from 8 chronically-infected
donors. Of the 70 pairs tested, 49 responses were found to have a reduced AE magnitude as
compared to the observed NAE response (p<0.0001 by Wilcoxon ranked pairs) (Fig 2A).
The finding that the NAE induced a higher magnitude of responses compared to their AE
counterparts can be explained by at least two different scenarios. First, as it is well known that
autologous viral sequences are better at eliciting T-cell responses [24], the limited AE immuno-
genicity could reflect chronically-infected individuals having virus encoding a predominance
of NAE. An alternative explanation is that AE are the result of host immune pressure on NAE
epitopes and subsequent viral escape. To explore these alternatives, we performed population
viral sequencing, determining the dominant form of the virus in the 5 CHI individuals who
demonstrated responses to the predicted epitopes and for whom plasma/PBMC samples were
available (2 controllers and 3 non-controllers, S4 Table). We determined whether the dominant
autologous viral sequence matched the NAE or AE at the amino acid from the identified poly-
morphic site (Fig 2B). The highest frequency of responses (71%) was observed in patients
whose autologous sequence matched the non-adapted form and who were subsequently stimu-
lated with NAE (p = 0.04 compared to AE). Conversely, in 5/23 cases (22%) where the domi-
nant viral quasispecies encoded the AE form, NAE was found to be immunogenic, which was
not significantly different from the immunogenicity of the matching AE (10/23 or 43%).
Fig 1. Novel HLA-II-restricted HIV-1 specific epitopes stimulate CD4+ T cell responses during chronic HIV infection. (A) Peptide pools containing the
predicted CD4+ T cell epitopes (NAE and AE forms) were tested among HIV seronegative individuals (SN = 10), non-controllers (NC = 14), and controllers
(C = 14) in an IFN-γ ELISpot assay. The magnitude of IFN-γ response (SFC/106 PBMC) for all three groups is shown. Each dot represents a response to a
single peptide pool, the dotted line demarcates the threshold for a positive ELISpot response (>50 SFC/106). Mann-Whitney U test was used to calculate
statistical significance, with error bars representing the SEM. (B) The percentage of patients responding to single peptide (NAE and AE forms) stimulations
encompassing the 29 unique HLA-II associated polymorphic sites (shown by the numbering position within each protein, X-axis) as measured in an IFN-γ
ELISpot assay is indicated for controllers (middle panel) and non-controllers (right panel).
doi:10.1371/journal.ppat.1005111.g001
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PLOS Pathogens | DOI:10.1371/journal.ppat.1005111 August 24, 2015 5 / 19
Prior work has shown CD8+ T-cell mediated antigen sensitivity (functional avidity) is a reli-
able predictor of viral control [25,26]. To determine whether this was also evident in epitope-
specific CD4+ T cells, we determined the antigen sensitivity of immunogenic NAE and AE
where the epitope sequence matched the dominant viral species present in the respective
Fig 2. Adapted CD4+ T cell epitopes have reduced immunogenicity in chronic infection. (A) Magnitude of CD4+ T cell responses to NAE vs. AE
evaluated in PBMC obtained from 8 (5 controllers and 3 non-controllers) HIV-1 chronically-infected donors using an IFN-γ ELISpot assay is shown. Each dot
represents a single NAE or AE response. Filled and open dots indicate AE responses that are lower or higher in magnitude, respectively, as compared to
their paired NAE responses. Wilcoxon matched-pairs signed rank test was used to determine statistical significance. (B) The dominant autologous viral
sequences from 5 chronically infected patients (NC1, NC2, NC5, C4, and C6) were obtained. On an epitope basis, each sequence was then compared to see
whether it matched an NAE or an AE. Examples of an NAE (Gag339) and AE (Nef104) matching the autologous sequence are shown. Polymorphic amino
acids in viral sequences are bolded. Overall frequency of NAE and AE responses (N = 5) as determined in an IFN-γ ELISpot assay in donors with autologous
sequence matching either NAE or AE is shown. The fraction on top of each bar indicates the number of positive responses out of the total number of peptides
tested. (C) CD4+ T cells expanded 10 days in vitro with sequence-matched and mismatched peptides were used as effectors and CD4+ T cells from
autologous and HLA-II mismatched individuals, pulsed with peptides of the same specificity as the effectors, were used as targets at various E:T ratios of
0.5:1, 1:1, and 1.5:1 for 24 hrs. Effector CD4+ T cell-mediated killing was determined by the percentage of 7-AAD+ targets in the presence of effector adjusted
relative to % 7-AAD+ target cells without any effectors (E:T of 0:1). Graphical depiction comparing NAE and AE-specific CD4+ T cell induced killing is shown
for a controller (C6) and a non-controller (NC5).
doi:10.1371/journal.ppat.1005111.g002
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patients. We tested CD8-depleted PBMCs from five different patients with 6 NAE/AE
responding pairs of peptides. The functional avidity did not significantly differ between NAE
and AE, with a higher NAE magnitude observed only at the lowest 10−7 M peptide concentra-
tion tested (S3 Fig).
Since polyfunctional CD4+ T cells, especially those making granzyme A, have been impli-
cated in viral control [27], we next evaluated the functionality of antigen-specific CD4+ T cells
using multiparametric flow. PBMCs from 4 CHI patients were stimulated ex vivo and evaluated
in an intracellular cytokine staining assay. We observed similar up regulation of cytokines and
cytotoxic factors by CD4+ T cells for both NAE and AE specific responses (S4 Fig).
We next wanted to assess whether both NAE and AE-specific CD4+ T cells can effectively
kill HIV targets. Autologous as well as HLA-II mismatched CD4+ T cell targets (as a negative
control) were pulsed with either NAE or AE peptide and then co-cultured with the respective
NAE or AE effector cells. Using a 7-AAD assay, we observed higher CD4-mediated killing of
autologous NAE-pulsed targets, relative to HLA-II mismatched targets, but killing of AE-
pulsed targets was significantly impaired (Fig 2C).
CD4+ adapted epitopes (AE) are poorly immunogenic during acute
infection
A limitation to studies in chronically-infected HIV patients is that they harbor highly heteroge-
neous HIV-1 variants. Therefore, it is not possible to ascertain whether an immune response
reflects a de novo response elicited by that epitope or cross presentation of an epitope variant.
To accurately identify epitope-induced responses, we used single genome amplification tech-
nique [28–30] to obtain transmitted founder virus (TFV) sequences from the plasma of 11
clade B acutely infected patients (Fiebig stages I-III, S2 Table). Taking into consideration each
donor’s HLA-II alleles, we determined the number of NAE and AE encoded by TFV that estab-
lished infection in each acute patient (number of encoded NAE and AE for a representative
patient is shown in S5 Table). While the number of transmitted NAE and AE varied from indi-
vidual to individual (range of 2–10 for NAE, 2–7 for AE), the median numbers encoded by the
TFV per infected individual were similar (Fig 3A), indicating that transmission of CD4+ AE
variants is relatively common. Overall, in these 11 patients, we identified 52 and 53 predicted
NAE and AE, respectively, encoded in the TFV. After stimulating each patient’s PBMC with
Fig 3. CD4+ T cell adapted epitopes (AE) are poorly immunogenic during acute infection. (A) Median number of NAE and AE encoded by transmitted
founder virus (TFV) that infected each of the 11 acute patients is indicated. Error bars represent the interquartile range of the median. (B) For each unique
HLA-II predicted epitope, relevant NAE or AE peptide matching the determined TFV sequence was tested in IFN-γ ELISpot. Percentage of NAE or AE that
was immunogenic in at least one patient is shown. Fractions represent number of epitopes that elicited a response / total number of epitopes tested. Fisher’s
exact test was used to determine significance.
doi:10.1371/journal.ppat.1005111.g003
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the appropriate TFV-encoded epitopes (NAE or AE) in an IFN-γ ELISPOT assay, only 1/53
AE peptide elicited an immune response versus 9/52 NAE specific responses (p = 0.008) (Fig
3B). Each predicted polymorphism represents a possible CD4+ T-cell escape mutation, as AE
are poorly immunogenic even when encoded by the TFV. The presence of AE in the TFV,
therefore, possibly represents CD4+ T cell epitopes that have escaped in a prior host.
CD4+ T cell responses are temporally associated with predicted escape
following acute infection
We next analyzed longitudinal sequence data from two distinct acute infection cohorts to look
for evidence of longitudinal HIV sequence changes based on HLA-II associated HIV-1 poly-
morphisms. As shown in Fig 4A, we observed 9 changes reflective of escape and 14 of reversion
Fig 4. Evidence for CD4 T-cell escape following acute infection in HIV-1 clade C infected patients. (A) HIV sequence data and HLA alleles were
obtained from two distinct cohorts of acutely infected individuals followed longitudinally (N = 99) and were used to determine the frequency of escape and
reversion. (B) Longitudinal changes in viral load are shown at the CD4+ T cell pre-escape and escape time points for 5 donors on whom data was available.
Patient AH-5 is from cohort 1 and the remaining 4 are from cohort 2. Statistical significance was determined using Wilcoxon matched-pairs signed rank test.
(C) Using an IFN-γ ELISpot assay, responses to the NAE and AE forms of Pol 68 epitope were evaluated using PBMCs from donors AH-1 and AH-2. (D)
PBMCs from patient AH-3 were expanded 10 days in culture and then stimulated with NAE and AE forms of Pol 161 epitope in IFN-γ ELISpot assay. Bold
indicates time points when PBMCs were available for testing.
doi:10.1371/journal.ppat.1005111.g004
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among the 99 patients in these cohorts. In each of the 5 patients, where longitudinal viral load
data (pre and post escape) were available, there was a non-significant increase in viral load at
the time point immediately following escape (mean VL increase of 72,675 copies,
SEM = 36,337, p = 0.06; Fig 4B), as compared to the time point preceding escape. Further anal-
ysis revealed no evidence of viral sequence changes at known CD8 polymorphic sites at these
time points for each of the 5 donors reported and their respective repertoire of HLA-I alleles.
We next looked for biologic evidence of viral escape. Limited access to samples and dimin-
ished CD4+ T cell responses in cryopreserved specimens restricted these studies [31]; however,
we identified samples from time points with evidence of viral escape at predicted polymorphic
sites and tested CD8-depleted PBMCs for immunogenicity to the NAE and AE in 6 patients.
We found biologic evidence of viral escape in 3 of these 6 donors, with 2 instances at the Pol 68
epitope (Fig 4C) and one at the Pol 161 epitope (Fig 4D). Based upon TFV sequence data, each
individual was determined to have been infected with the NAE form at the polymorphic site
before the AE became the dominant sequence at a later time point. In each case, NAE stimula-
tion elicited a response from CD8-depleted PBMCs prior to the predicted escape. In AH-1, a
robust ELISpot response to the NAE was observed immediately prior to viral escape at the
18-month time point; no response to the AE was observed. For this patient, samples from later
time points were not available. In AH-2, a modest ELISpot response to the NAE was observed
immediately prior to escape at the 9-month time point. At the subsequent 12-month collection
time, the NAE response was lost; a response to AE at either time point was not observed. In
AH-3 (Fig 4D), initial ELISpot screening was negative for the NAE and AE at time points 12,
18 and 21 months, however cultured ELISpot revealed evidence of the NAE but not AE
response prior to viral escape at 18 months. This response was lost at the 21-month time point.
Discussion
HIV-specific CD4+ T cells have been relatively understudied compared to other arms of the
adapted immune response. Prior studies of HIV pathogenesis identified an association between
preserved CD4+ T cell function and improved clinical progression [32], but a lingering ques-
tion has been whether the observed CD4+ T cell function simply reflects immune preservation
or that this cell population influences viral immune control. Recent studies have demonstrated
HIV-specific CD4+ T cell responses correlate with viral control [27] as has been demonstrated
with CD8+ T cells in the past [33,34]. Furthermore, emerging data indicate that HIV-specific
CD4+ T cells with cytolytic potential are especially important in early viral control [35]. These
works suggest that CD4+ T cells should force HIV escape mutations similar to what has been
extensively observed for both CD8+ T cells and neutralizing antibodies. However, prior studies
have suggested that CD4+ T cells exert only limited selective pressure on HIV [12,36–38].
Definitive CD4+ T cell escape has been reported in SIV, but this was only described in a single
rhesus macaque at a single epitope [13].
Here we demonstrate multiple lines of evidence for HIV escape from CD4+ T cell responses.
Similar to HLA-I associated HIV polymorphisms, HLA-II associations were used to predict 29
sites representing viral evolution. While we did not formally demonstrate that each of these
predictions represented an escape, it is interesting that every one of the predicted epitopes was
found to be immunogenic. Furthermore, non-escaped epitopes or NAE were more immuno-
genic than AE in chronic infection, a finding not explained by preferential infection by viruses
encoding NAE. Moreover, AE were poorly immunogenic in acute HIV infection where limited
viral diversity of the TFV ensures the identity of the epitope eliciting the observed immune
response as either NAE or AE. Finally, in 2 cohorts of acutely infected patients followed off
ART for 2 years, we see evidence for CD4+ escape and temporally associate three of these
HLA-II Adaptations and HIV Infection
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responses with subsequent escape. Interestingly, several of the polymorphisms identified in
this study reverted following infection into hosts no longer able to target the epitope, suggesting
CD4+ T cell-induced escapes impose a viral fitness cost as has been demonstrated extensively
for CD8+ T cells. This observation is consistent with HLA-I-restricted escape in which protec-
tive alleles drive escape associations at more sites and with larger effect sizes, suggesting a
model in which the presence of detectable selection pressure corresponds to effective CD8 or
CD4-mediated killing [18]. In sum our data provide strong evidence for CD4+ T cell responses
influencing viral evolution.
Despite the fact that HIV escapes from CD8+ T cells, neutralizing antibodies, and even NK
cells [1–4,6,39], it is interesting that escape from CD4+ T cells has been much more difficult to
document [10–12]. This may be partially attributable to the prominence of CD8+ T cell escape,
thus making it difficult to separate the effect of this immune response from those induced by
CD4+ T cells. Our findings suggest CD4-mediated escape happens on a larger scale than previ-
ously appreciated, although it is unlikely to be as prevalent as CD8-mediated escape. Another
difficulty in defining HLA-II polymorphisms is that HLA class II alleles bind epitopes much
more promiscuously compared to HLA-I, making it more difficult to assign the polymorphism
to a specific HLA-II allele. In patients with chronic infection, we mapped positive responses in
donors that had the model predicted HLA-II allele, but also observed responses in donors that
did not have the predicted allele. In light of the promiscuity of HLA-II binding, it is not surpris-
ing that HLA-II alleles other than those predicted by the model presented here can also present
the epitopes of interest. The promiscuous response of HLA-II alleles is almost certainly influ-
encing HIV at polymorphic sites other than those predicted by this particular model, but these
changes are obfuscated by the contribution of multiple alleles. Nevertheless, the observation of
compromised immunogenicity of AE in the setting of acute infection was restricted to studies
of donors expressing the predicted HLA-II alleles, thereby strengthening the likelihood that
HLA-II associated HIV polymorphisms predict escape from CD4 T cells. The predictions were
based on HIV (gag, pol, and nef) and HLA-II sequences in 348 Zambians with chronic HIV
infection, and it seems likely that further polymorphisms can be identified by studying more
individuals and additional HIV proteins [18–20,40,41].
Our findings convincingly demonstrate both that CD4+ T cells respond to the predicted
panel of polymorphic epitopes, and viral sequence change to the adapted form compromises
this response. Nevertheless, CD8+ T cell responses are highly prevalent in HIV infection, so to
address the possibility that CD8 responses may be driving viral escape we looked for CD8+ T
cell responses to peptides yielding positive CD4+ T cell responses in a flow-based assay. In 7
unique donors we tested 19 peptides and observed CD4+ but not CD8+ T cell responses to the
peptides. We also noted that none of the HLA-II alleles for which we observed polymorphisms
were in significant linkage disequilibrium with HLA-I alleles. The one exception was that
DQB106 is in negative linkage with HLA-B57, yet both are associated with a p24 polymor-
phism at position 247 (S6 Table). Indeed, the one individual who had a response to the pre-
dicted CD4 epitope was DQB106 positive and HLA-B57 negative. These findings speak to
the possibility that multiple immune parameters (in this case both CD4+ and CD8+ T cells) are
driving viral evolution independently and further solidify our results.
Although the HLA-AP presented here were derived from a clade C infected African cohort,
their immunogenicity was evaluated in both clade B and C infected samples. The consistent
immunogenicity across clades suggests the predicted CD4 epitopes are shared to some extent
in HIV-1 infection by different subtypes. Similar to HLA-I associated escape, site-specific viral
escape may be maintained across clades [42]. Genome-wide association study (GWAS) has
previously failed to identify HLA-II alleles that are associated with viral control, which may
reflect the promiscuity of antigen presentation. Furthermore, unlike HLA-I alleles that encode
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a single heavy chain responsible for peptide loading and interaction with TCR, HLA-II must
function as a heterodimer consisting of an alpha and beta chains. Association analyses facili-
tated by GWAS only assess one polymorphism at a time without testing their combinations;
the ability of such an approach to accurately capture HLA allelic function is much less accurate
for HLA-II alleles [43]. Prior work implicated gag-specific CD4+ responses as most relevant to
viral control [27,44], whereas our predictions had limited associations within Gag. A prior
investigation did attempt to identify HLA-II polymorphisms using a cohort approach [38].
This analysis was done in Gag-Protease and used a similar but distinct computational method
[42]. By applying a revised method [18] and extending our analysis to the rest of Pol and Nef,
we identified a number of polymorphisms that were then tested biologically for validity. The
majority of our predictions were outside of Gag, which would not have been picked up in this
prior analysis.
An important question arising from these studies concerns whether HIV-specific CD4+ T
cells are playing a role in viral control. The fact that they are pressuring the virus to mutate to
avoid CD4 responses certainly suggests that they do contribute to this process, albeit at a mag-
nitude that is likely much less than CD8 responses. Furthermore, our findings demonstrate the
ability of HIV-specific CD4+ T cells to induce viral escape and suggest that such escapes are
not rare events. These results should serve as a springboard for future research to definitively
determine the role of HIV-specific CD4+ T cells in viral control.
Materials and Methods
Ethics statement
Chronic and acutely-infected individuals from Zambia provided written, informed consent to
the Zambia University Teaching Hospital ethics committee and the Emory University institu-
tional review board (IRB) prior to collection of information. Additional patients were recruited
from the University of Alabama at Birmingham Adult AIDS 1917 clinic after obtaining written,
informed consent and approval from the IRB at UAB.
Study cohorts
A cohort of 348 Zambian individuals chronically infected with HIV-1 subtype C had the gag,
pol, and nef gene viral sequences determined by population sequencing. Virus from an addi-
tional 81 acutely infected individuals from the Zambian cohort was sequenced longitudinally
and PBMC from five of these HIV-1 subtype C-acutely infected ART naïve Zambian patients
were used in this study. These patients were recruited at the Zambia-Emory HIV Research
Project (ZEHRP) in Lusaka, Zambia into the ZEHRP heterosexual transmission discordant
couple cohort and the International AIDS Vaccine Initiative (IAVI) Protocol C; informed con-
sent was obtained from all patients. HIV sequences were also obtained from 18 subtype-C
acutely infected patients from the CHAVI cohort [29]. For the IAVI cohort, the earliest viral
sequences were obtained approximately 1–2 weeks post-infection. For the Zambian cohort, the
first sequences were obtained approximately 3 months post infection. Both cohorts are hetero-
geneous with regards to when escape or reversion occurred, as that is different for each individ-
ual. Escape was noted to occur as early as two weeks or as late as 24 months post infection;
reversion occurred as early as 6 months or as late as 24 months post infection.
Cryopreserved PBMC samples from ART naïve HIV-1 clade B chronically infected patients
(N = 28) (S1 Table) and acutely infected patients (N = 11) (S2 Table) were used in this study.
The chronic cohort included HIV controllers (n = 14, VL<2,000 copies/mL) and HIV non-
controllers (n = 14, VL>10,000 copies/mL); both off ART. Details on the demographics and
clinical features of these chronically infected individuals are shown in Tables 2 and S1. Acute
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HIV infection was stratified by the Fiebig staging. Healthy HIV seronegative donors (N = 10)
from the Alabama Vaccine Research Clinic were used as controls.
HLA-II genotyping
High-resolution (4-digit) genotyping data for the Zambian cohort came from earlier work
[43]. For additional genotyping, we applied two molecular techniques to define HLA-DRB1
andHLA-DQB1 alleles in local patients. The procedures for sequencing-based typing (Abbott
Molecular Inc., Des Plaines, IL) and automated DNA hybridization with oligonucleotide
probes (Innogenetics Inc., Alpharetta, GA) have been described elsewhere [45,46]. Assignment
of 2-locus haplotypes was based on known patterns of linkage disequilibrium in African Amer-
ican and European American populations.
HLA-II associated HIV-1 polymorphisms prediction
We identified HIV polymorphisms in HIV gag, pol, and nef that were statistically enriched in
348 chronically clade C infected, antiretroviral-naïve Zambian individuals expressing specific
HLA-II alleles. We then performed phylogenetically corrected logistic regression as imple-
mented in the PhyloD software [42]. This approach takes as input a protein-specific phyloge-
netic tree (as inferred by Phyml 3.0 [47]), HIV sequences, and putative predictor variables.
Separate phylogenetically corrected logistic regression models are inferred for each amino acid
at each site, using forward selection to select features and computing p-values using likelihood
ratio tests. Overall significance is reported as q-values, which estimate the false discovery rate
associated with each p-value [48]; q<0.2 was chosen as a threshold for experimental follow up.
Only features (amino acids at a given site, class I and class II alleles, at 2- and 4-digit resolution)
that were observed in at least 3 (and at most N = 3) individuals were considered.
Our initial application of PhyloD closely followed previously published applications [18],
with the exception that both class I and class II alleles were included as predictor variables.
This approach yielded seven sites for which at least one amino acid was positively or negative
associated with at least one HLA-II allele, called a “class-II-associated site”. An important
caveat to this approach is that amino acid mixtures present a problem to logistic regression.
Typically, PhyloD treats mixtures as uncertain observations by creating equally weighted frac-
tional observations. However, HIV mixtures may represent positive evidence for incomplete
selection. We therefore ran a second analysis in which all mixture amino acids were treated as
positive observations of polymorphic amino acids. This analysis resulted in 16 class-II-associ-
ated sites. Although some of these sites overlapped with the initial eight sites, the specific alleles
and amino acids differed, perhaps indicating different intensities of selection pressure. Finally,
we reasoned that class I alleles may serve as the dominant source of selection pressure for most
sites. We therefore reran the analysis (treating mixtures as noisy observations, as in the first
analysis) such that forward selection preferentially added class I alleles and co-varying amino
acids. Specifically, class I alleles and co-varying amino acids were greedily added to the model
using a threshold of p<0.05. Class II alleles were considered only when no other amino acid or
class I allele significantly improved model fit. This analysis resulted in nine class-II-associated
sites, again with little overlap with the previous two analyses. Our overall analysis yielded 29
unique sites.
Because our aim in these statistical analyses was to guide experiments, we chose to follow up
with all 29 class-II-associated sites that resulted from these three approaches. Using the consen-
sus clade-B sequence, a 31 amino acid sequence was selected (15 amino acids upstream/down-
stream of the polymorphism). This sequence was then input into the Net MHCII prediction
software (http://www.cbs.dtu.dk/services/NetMHCIIpan). Using the class-II allele associated
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with each unique polymorphism, a 20-mer amino acid sequence with the highest HLA-II bind-
ing affinity (IC50< 500 nM) was selected for synthesis and immunogenicity testing. These
polymorphism containing epitopes are henceforth referred to as adapted epitopes or AE. For
each predicted adapted epitope, a corresponding consensus peptide (non-adapted epitope or
NAE) was also synthesized. In those cases where the predicted adaptation mirrored the consen-
sus, the next most common form of clade-B amino acid residue occurring at the polymorphic
site was defined as the non-adapted form. This resulted in a panel of 70 total peptides that were
used to assess CD4+ T-cell reactivity. For the initial response screening, the peptides were
grouped into 17 pools with 4–5 peptides per pool.
Peptide synthesis
Peptides encompassing the predicted CD4+ T cell epitopes and the identified amino acid poly-
morphisms were synthesized by New England Peptide (NEP) in a 96-array format and were
reconstituted at 40mM in dimethyl sulfoxide and stored at -70°C until use.
IFN-γ ELISPOT assay
Amodified ELISPOT assay was performed as previously described [23,27]. Briefly, nitrocellu-
lose plates were coated with anti-IFN-γ antibody overnight. The next day, PBMC were CD8-
depleted using magnetic beads (Dynabeads CD8, Invitrogen), and the enriched CD4+ T cells
were plated at 100,000 cells/well and were stimulated with the appropriate peptide pool or
single peptide at a final concentration of 10uM for 40h at 37°C and 5% CO2. The cells were
washed, and biotinylated anti-IFN-γ antibody was added to the plate for 2 hrs. After this incu-
bation, streptavidin-alkaline phosphatase was added for 1hr before applying BCIP/NBT sub-
strate for spot detection. The number of IFN-γ responses were enumerated using an ELISPOT
plate reader (CTL S6 Ultra-V Analyzer) and the data normalized to Spot Forming Cells per
million (SFC/106). A positive response was defined as 50 SFC/106 PBMCs or greater and at
least 2.5 times background (unstimulated media only wells). Phytohemagglutinin (PHA) was
used as a positive control. In certain cases where no detectable ex vivo response was apparent,
CD8-depleted PBMCs were cultured in the presence of peptide (10uM), IL-7 (25ng/ml) and
IL-2 (50IU/ml) for 7–10 days. Expanded antigen specific cells were then re-stimulated with
peptide in an IFN-γ ELISpot assay as described above.
Antigen sensitivity or functional avidity
To determine avidity, four 10-fold serial dilutions of peptides were used in an IFN-γ ELISPOT
assay as described above. Antigen sensitivity was determined by the peptide concentration that
elicited 50% of maximal IFN-γ response (EC50) for any given epitope.
Intracellular cytokine staining (ICS)
Flow cytometry based ICS assay was done as previously described [35,49,50]. In brief, 106
PBMCs were pulsed with peptide at 10uM in the presence of co-stimulatory antibodies (anti-
CD28 and anti-CD49D) and anti-CD107a-FITC (all from BD Biosciences) for 2 hrs at 37°C.
Monensin and brefeldin A (both from BD Biosciences) were then added and the cultures incu-
bated for an additional 12 hrs. Next day, the cells were labeled with LIVE/DEAD cell dye (Invi-
trogen) and surface stained with anti-CD3-Pac Blue, anti-CD8-V500, and anti-CD4-Alexa 780
(both from BD Biosciences). The cells were permeabilized and labeled with anti-IFN-γ-Alexa
700, anti-IL-2-APC, anti-TNFα-PECy7, and anti-Granzyme A-PE (all from BD Biosciences).
CD3 events greater than 100,000 were acquired on an LSR II (BD Immunocytometry Systems),
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and data were analyzed using FlowJo (version 9.6.4; TreeStar). Polyfunctionality analysis was
performed using Boolean gating and SPICE and Pestle software (version 5.1; NIAID).
HLA-II restriction using an IFN-γ based ELISPOT assay
HLA-II restriction assay was done essentially as described before [22,23]. In-vitro expanded
CD4+ T cell lines were used as effectors and peptide pulsed RM3 cell line transfectants were
used as antigen presenting cells (APC). In brief, CD8-depleted CD4+ T cells were cultured in
the presence of IL-7 (5ng/ml), nevirapine (1ug/ml), IL-2 (50IU/mL) and peptide (5uM) for
14 days. The RM3 cell lines were propagated, pulsed with peptide (10uM) for 3 hrs and then
washed thoroughly to get rid of excess peptide. The effectors (expanded CD4+ T cells) and the
targets (peptide pulsed RM3 cell lines) were plated at 50,000 and 100,000 cells/well, respectively
(i.e. 1:2 E/T ratio in an ELISPOT assay). The culture was then incubated for 24 hrs at 37°C and
5% CO2. We used HLA-II expressing RM3 cell lines relevant to the patient’s HLA-II allele and
determined the IFN-γ production when these lines were either not pulsed or pulsed with a pep-
tide that a) elicited a response previously and b) was predicted to be restricted by the same
HLA-II as the HLA-II transfected cell line that was used as APC. We used two negative con-
trols: an HLA-II mismatched irrelevant peptide and a cell line that did not express any of the
patient’s HLA-II alleles.
Viral RNA/genomic DNA extraction and cDNA synthesis
Viral RNA and genomic DNA were extracted from plasma (3 CHI donors) or PBMC (2 CHI
donors) by using the QIAamp RNA and DNAmini kits (Qiagen, Valencia, CA), and cDNA
synthesis was carried out using Superscript III (Invitrogen). Reverse transcription of extracted
RNA was performed, in two stages: in the 1st stage incubation was set at 50°C with 5U of
reverse transcriptase (RT) for 1 hour in the presence of 0.5 mM of each dNTP, 5 mM DTT,
2U/μl RNaseOUT (RNase inhibitor), and 0.25 mM antisense primer; the 2nd stage involved
incubation at 55°C with an additional 5U of RT for 2 hours. Synthesis was initiated by reverse
primer: 5’-ACTACTTAGAGCACTCAAGGCAAGCTTTATTG-3’ [51] and terminated by
incubation at 70°C for 15 min, followed by 20 min at 37°C with 1μl RNase H. The cDNA was
used immediately for near full-length HIV-1 PCR amplification.
Full-length HIV-1 genome amplification used forward primer 1.U5Cc—HXB2 positions
538–571–5’-CCTTGAGTGCTCTAAGTAGTGTGTGCCCGTCTGT-3’, and reverse primer
1.3’3’PlCb at HXB2 positions 9611–9642–5’-ACTACTTAGAGCACTCAAGGCAAGCTTTA
TTG-3’; the 2nd round primers were: Forward primer 2.U5Cd at HXB2 positions 552–581–5’-
AGTAGTGTGTGCCCGTCTGTTGTGTGACTC-3’ and reverse primer 2.3’3’plCb at HXB2
positions 9604–9636–5’-TAGAGCACTCAAGGCAAGCTTTATTGAGG-3’ [51]. PCR reac-
tions were carried out by using the Q5 High-Fidelity DNA Polymerase (New England BioLabs,
Catalog# M0491) with final concentration of 1X 5X Q5 Reaction Buffer, 1X 5X Q5 High GC
Enhancer, 200μM dNTPs, 0.5μM forward and reverse primers, and 0.02 U/ul Q5 DNA Poly-
merase. After initial 45 seconds of denaturing at 98°C, 30 cycles at 2-step temperatures involv-
ing 15 seconds denaturing at 98°C and 8 minutes annealing + extension at 72°C were done to
carry out the entire amplification. The final PCR product was stabilized at 72°C for 10 minutes
and incubated at 4°C until analysis.
The entire ~9kb PCR fragments were sequenced using Pacific Biosciences SMRT Se-
quencing Technology and DNA Library was built by using SMRTbell Template Preparation
Reagent Kits 1.0 with 3ug purified (Promega Wizard1 SV Gel and PCR clean-up System) PCR
product that contains 28 near full-length PCR reactions, which were derived from plasma or
PBMC from all 5 patients. The library was examined by 2100 Bioanalyzer for purity and
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concentration. SMRT sequencing was carried out using the P4C2 chemistry with 1x120min
acquisition mode on the PacBio RS according to standard protocol [52,53]. Data was analyzed
using an in-house developed computational code. The final product yielded 19 (median 5)
near full-length HIV-1 genomes.
Gene sequences for the above chronic donors have been submitted to GenBank, serial num-
bers pending. Acute sequences have either previously been reported [54], or have pending
serial numbers.
Assessing CD4-mediated killing using 7-aminoactinomycin D (7-AAD)
staining
7-AAD assay was performed according to a modified protocol based on a prior study [55].
PBMCs from autologous or complete HLA-II mismatched HIV seropositive donors were used
as target cells. CD4+ T cells were isolated from the PBMCs by CD8-depletion (Dynabeads
CD8, Invitrogen) and activated with PHA (5μg/mL) in the presence of IL-2 (100IU/mL) for
2 days. Similar to prior studies [56], activated CD4 targets (1x105 cells) were CFSE-labeled and
were pulsed with the relevant HIV-1 NAE or AE peptide at 10uM for 1h before co-culturing
with the appropriate NAE or AE-specific CD4+ T-cell line for 24 hrs at various E/T ratios (0:1,
0.5:1, 1:1, and 1.5:1). After incubation, the cells were surface stained with anti-CD3-Pac Blue
(BD Biosciences) and anti-CD4-Alexa780 (eBioscience) before washing and staining with
0.25ug of 7-AAD (BD Biosciences) for 20 min at 4°C. Using flow cytometry, antigen-specific
killing was determined by comparing the percentage of 7-AAD+ CD4 T cells in the presence of
effector CD4 line relative to that in the absence of effector line (S5 Fig).
Statistical analysis
Statistical tests were carried out using Fisher’s exact test, paired t-test, and nonparametric
Mann-Whitney U. GraphPad Prism software (version 5.0) was used to perform these analyses.
A p value of<0.05 was considered statistically significant.
Supporting Information
S1 Fig. Flow cytometry gating strategy for a representative HIV-1 controller and a non-
controller. Flow cytometry plots depicting purity of CD8 depletion for a controller (top panel)
and a non-controller (bottom panel) are shown.
(TIFF)
S2 Fig. Novel CD4+ T cell epitopes are restricted by predicted HLA-II alleles. Shown is the
HLA class II restriction of (A) DRB113-restricted Gag peptide (sequence: CKTILKALGP
AATLEEMMTA) and (B) DRB103-restricted Nef peptide (sequence: MRRAEPAADGVGA
VSRDLEK) as determined in an IFN- ELISpot assay using PBMC samples from chronically
HIV infected patients–C1 (DRB113:02, DRB115:03, DQB103:03, DQB105:01) and NC1
(DRB103:01, DRB113:01, DQB102:01, DQB106:03). Effectors were CD4+ T cells expanded
short term in vitro and the APC were transfected HLA-II expressing RM3 cells pulsed with
the cognate peptide. The HLA-II matched and mismatched RM3 lines express DRB113:02
and DRB103:02, respectively, for restriction experiment done in (A), and DRB103:02 and
DQB105:01, respectively, in (B). Error bars in (A) represent the SEM from duplicate experi-
ments.
(TIFF)
S3 Fig. Functional avidity of NAE and AE epitopes. Graphical representation of antigen sen-
sitivity responses is shown in four NAE/AE pairs where the donor sequence matches the NAE,
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and for 2 NAE/AE pairs where the donor sequence matches the AE. Error bars represent the
SEM from duplicate experiments. Wilcoxon matched-pairs signed rank test was used to deter-
mine statistical significance ().
(TIFF)
S4 Fig. Epitope-specific CD4 T cells produce cytolytic molecules. A) Representative flow
cytometry plots on IFN-γ/CD107a and IFN-γ/Granzyme A producing CD4 T-cell responses to
a DQB102-restricted non-adapted epitope (NAE) from a chronically infected patient are
shown. (B) The overall ex vivo polyfunctionality of cytokine/effector molecule production of
CD4 responses (5 functions) to 5 pairs of non-adapted (NAE) and adapted (AE) epitopes
from 4 patients (2 controllers and 2 non-controllers) was evaluated using ICS and SPICE and
PESTLE software. IFNg = IFN-γ; IL2 = IL-2; TNFa = TNF-α; CD107a = CD107a; Gran
A = Granzyme A
(TIFF)
S5 Fig. Representative 7-AAD killing assay for NAE and AE-specific CD4 T cells. Flow
cytometry plots on 7-AAD staining of apoptotic target cells for a representative DQB106:11
restricted NAE/AE CD4 mediated killing in patient C6 are shown.
(TIFF)
S1 Table. Clinical and demographic features of chronically HIV-1 infected cohort used in
this study.
(PDF)
S2 Table. Clinical and demographic features of acutely HIV-1 infected cohort in the study.
(PDF)
S3 Table. HLA class II epitopes with the predicted polymorphisms that were evaluated for
immunogenicity.
(PDF)
S4 Table. Aligning predicted non-adapted and adapted epitope sequences with autologous
viral sequences in controllers (C) and non-controllers (NC).
(PDF)
S5 Table. Example of HLA-II relevant epitopes tested in acute patient (PHI-4).
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S6 Table. Possible HLA-I linkage with HLA-II associated HIV-1 polymorphisms.
(PDF)
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